Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer-Reference-Cited by-同舟云学术

Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer

Published:2008-02 Issue:2 Volume:7 Page:424-430
ISSN:1535-9476
Container-title:Molecular & Cellular Proteomics
language:en
Short-container-title:Molecular & Cellular Proteomics

Author:

Würtz Sidse Ørnbjerg,M⊘ller Susanne,Mouridsen Henning,Hertel Pernille Briæmer,Friis Esbern,Brünner Nils

Publisher

Elsevier BV

Subject

Molecular Biology,Biochemistry,Analytical Chemistry

Reference23 articles.

1. Meeting highlights: international expert consensus on the primary therapy of early breast cancer;Goldhirsh;Ann. Oncol.,2005

2. Do we need better prognostic factors in node-negative breast cancer?;Thomssen;Eur. J. Cancer,2003

3. High levels of messenger RNAs for tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases;Ree;Clin. Cancer Res.,1997

4. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis;Nakopoulou;J. Pathol.,2002

5. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with primary breast cancer;McCarthy;Int. J. Cancer,1999

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TIMP1 shapes an immunosuppressive microenvironment by regulating anoikis to promote the progression of clear cell renal cell carcinoma;Aging;2023-09-08

2. Quantification of MMP-2 and TIMP-1 expressions in breast cancer;İstanbul Journal of Pharmacy;2023-08-28

3. TIMP1 Expression Level Predicts Worse Prognosis in Kidney Renal Clear Cell Carcinoma;J BIOL REG HOMEOS AG;2023

4. Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression;International Journal of Molecular Sciences;2023-01-22

5. Matrix metalloproteinases as therapeutic targets in breast cancer;Frontiers in Oncology;2023-01-19